COVID-19 Vaccines Under Pre-Clinical Development

1

DNA Vaccine

DNA with electroporation

Karolinska Institute / Cobra Biologics

2

DNA Vaccine

DNA plasmid vaccine

Osaka University/ AnGes/ Takara Bio

3

DNA Vaccine

DNA

Takis/Applied DNA Sciences/Evvivax

4

DNA vaccine (Nucleic acid based)

Plasmid DNA, Needle-Free Delivery; Immunomic’s UNITE platform, EpiVax’s in silico T cell epitope prediction tool, and PharmaJet’s Tropis® Needle-free Injection System

Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet

5

DNA vaccine

DNA plasmid vaccine

Zydus Cadila

6

DNA vaccine (Antibody response induced)

DNA vaccine

BioNet Asia

7

DNA Vaccine

DNA vaccine though nasal spray

University of Waterloo

8

bacTRL-Spike (DNA vaccine)

Orally administered, DNA Plasmid vaccine

Symvivo Corporation

9

DNA Vaccine

DNA vaccine

Entos Pharmaceuticals

10

DNA Vaccine (Linear DNA vaccine)

LineaRx's polymerase chain reaction (PCR)-based production platform

Linearx Inc.; Takis Biotech

1

Inactivated

Inactivated

Institute of Medical Biology, Chinese Academy of Medical Sciences

2

Inactivated

Inactivated

Beijing Minhai Biotechnology

3

Inactivated

TBD

Osaka University/ BIKEN/ NIBIOHN

4

Inactivated

Inactivated + CpG 1018

Sinovac/Dynavax

5

Inactivated

Inactivated + CpG 1018

Valneva/Dynavax

6

Inactivated

Inactivated

Research Institute for Biological Safety Problems, Rep of Kazakhstan

1

Live Attenuated Virus

Codon deoptimized live attenuated vaccines

Codagenix/Serum Institute of India

2

Live Attenuated Virus

Codon deoptimized live attenuated vaccines

Indian Immunologicals Ltd/Griffith University

1

Non-Replicating Viral Vector

MVA encoded VLP - GV-MVA-VLP vaccine platform

GeoVax/BravoVax

2

Non-Replicating Viral Vector

Adenovirus 26 (Ad26)

Janssen Pharmaceutical Companies

3

Non-Replicating Viral Vector

Replication defective Simian Adenovirus (GRAd) encoding SARS-CoV2 S

ReiThera/LEUKOCARE/Univercells

4

Non-Replicating Viral Vector

MVA-S encoded

DZIF – German Center for Infection Research

5

AdCOVID (Non-Replicating Viral Vector)

Adenovirus-based NasoVAX expressing
SARS2-CoV spike protein

Altimmune

6

Non-Replicating Viral Vector

Ad5 S (GreVac Plug-And-Play technology)

Greffex

7

OraPro-COVID-19 (Non-Replicating Viral Vector)

Oral Ad5 S

Stabilitech Biopharma Ltd

8

Non-Replicating Viral Vector

Adenovirus-based + HLA-matched peptides (PeptiCRAd technology)

Valo Therapeutics Ltd

9

Non-Replicating Viral Vector

VAAST Oral Vaccine platform

Vaxart

10

Non-Replicating Viral Vector

MVA expressing structural proteins

Centro Nacional Biotecnología (CNB-CSIC), Spain

11

Non-Replicating Viral Vector

Dendritic cell-based vaccine

University of Manitoba

12

Non-Replicating Viral Vector

parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein

University of Georgia/University of Iowa

13

Non-Replicating Viral Vector

Recombinant deactivated rabies virus containing S1

Bharat Biotech/Thomas Jefferson University

1

Protein Subunit

Capsid-like Particle

AdaptVac (PREVENT-nCoV consortium)

2

Protein Subunit

Drosophila S2 insect cell expression system VLPs

ExpreS2ion

3

DPX-COVID-19 (Protein Subunit)

Peptide antigens formulated in LNP

IMV Inc; University Laval

4

Protein Subunit

S protein

WRAIR/USAMRIID

5

Protein Subunit

S protein +Adjuvant

National Institute of Infectious Disease, Japan

6

Protein Subunit

VLP-recombinant protein + Adjuvant

Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan

7

Protein Subunit

Native like Trimeric subunit Spike Protein vaccine using CpG 1018 adjuvant

Clover Biopharmaceuticals Inc./GSK/Dynavax

8

Protein Subunit

Microneedle arrays S1 subunit

University of Pittsburgh

9

Protein Subunit

Peptide Vaccine (signal peptide technology) - VaxHit bioinformatics platform

Vaxil Bio

10

Protein Subunit

Adjuvanted protein subunit (RBD)

Biological E Ltd

Flowvax (Protein Subunit)

Peptide - Size Exclusion Antigen Presentation Control technology

Flow Pharma Inc.

12

Protein Subunit

S protein

AJ Vaccines

13

Protein Subunit

Ii-Key peptide vaccine

Generex/EpiVax

14

EPV-CoV19 (Protein Subunit)

S protein

EpiVax/Univ. of Georgia

15

Adjuvanted recombinant subunit vaccine (Protein Subunit)

S protein(baculovirus production) - recombinant spike protein antigen and its baculovirus expression system

Sanofi Pasteur/GSK

16

Protein Subunit

Immune-activating gp-96 platform

Heat Biologics/Univ. Of Miami

17

Protein Subunit

Molecular clamp stabilized Spike protein (Glaxosmithkline plc and Seqirus GmbH)
Toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 (Dynavax Technologies Corp. and University)

University of Queensland/GSK/Dynavax/Seqirus GmbH

18

Protein Subunit

Peptide vaccine

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

19

Protein Subunit

Subunit vaccine

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

20

Protein Subunit

S1 or RBD protein

Baylor College of Medicine

21

SARS-CoV-2 Virus-Like Particle (Protein Subunit)

Subunit protein, plant produced (FastPharming)

iBio/CC-Pharming

22

Protein Subunit

Recombinant protein, nanoparticles (based on S-protein and other epitopes)

Saint-Petersburg scientific research institute of vaccines and serums

23

COVID-19 XWG-03 (Protein Subunit)

Recombinant protein-based coronavirus vaccinebased on series of truncated S (spike) proteins

Innovax/Xiamen Univ./GSK

24

Protein Subunit

Adjuvanted microsphere peptide

VIDO-InterVac, University of Saskatchewan

25

Protein Subunit

Synthetic Long Peptide Vaccine candidate for S and M proteins

OncoGen

26

Protein Subunit

Oral E. coli-based protein expression system of S and N proteins

MIGAL Gaililee Research Institute

27

Protein Subunit

Nanoparticle vaccine

LakePharma, Inc.

28

Protein Subunit

Recombinant spike protein with Advax™ adjuvant

Vaxine Pty Ltd.

29

Protein Subunit

OMV-based vaccine

Quadram Institute Biosciences

30

Protein Subunit

OMV-based vaccine

BioMVis Srl/ University of Trento

29

TNX-1810, TNX-1820 and TNX-1830 (Protein Subunit)

Spike-based

Univeristy of Alberta/Tonix Pharmaceuticals Holding Corp

31

Protein Subunit

Structurally modified spherical particles of the tobacco mosaic virus (TMV)

Lomonosov Moscow State University

32

TNX-1810, TNX-1820 and TNX-1830 (Protein Subunit)

Spike-based

Univeristy of Alberta

33

Protein Subunit

Recombinant S1-Fc fusion protein

AnyGo Technology

34

Protein Subunit

Recombinant protein

Yisheng Biopharma

35

Protein Subunit

Recombinant S protein in IC-BEVS

Vabiotech

36

Protein Subunit

Orally delivered, heat stable subunit

Applied Biotechnology Institute, Inc.

37

Protein Subunit

S-2P protein + CpG 1018

Medigen Vaccine Biologics Corporation/NIAID/Dynavax

38

Protein Subunit

Peptides derived from Spike protein

Axon Neuroscience SE

39

Protein Subunit

Adjuvanted recombinant protein (RBD-Dimer)

Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences

40

Protein Subunit

RBD-based

Neovii/Tel Aviv University

41

Protein Subunit

RBD-based

Kentucky Biprocessing

42

Protein Subunit

Outer Membrane Vesicle (OMV)peptide

Intravacc/Epivax

1

Replicating Viral Vector

YF17D Vector

KU Leuven

2

Replicating Viral Vector

Measles Vector - development of a live attenuated recombinant measles virus vectored vaccine against COVID-19

Zydus Cadila

3

Replicating Viral Vector

Measles Vector - engineering of measles live-attenuated vaccine to express other antigens

Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research

4

Replicating Viral Vector

Measles Vector

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

5

Live attenuated virus

Measles Virus (S, N targets) - Developing a live-attenuated virus using measles virus technology

DZIF – German Center for Infection Research

6

TNX-1800 (Replicating Viral Vector)

Horsepox vector expressing S protein - a live modified horsepox virus vaccine for percutaneous administration, for the potential prevention of COVID-19

Tonix Pharma/Southern Research

7

Replicating Viral Vector

Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)

BiOCAD and IEM

8

Replicating Viral Vector

Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

9

Replicating Viral Vector

Attenuated Influenza expressing an antigenic portion of the Spike protein

Fundação Oswaldo Cruz and Instituto Buntantan

10

Replicating Viral Vector

Influenza vector expressing RBD - Developing a replicating viral vector vaccine

University of Hong Kong

11

Replicating Viral Vector

Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein. Replicating viral vector that expresses the S protein

International AIDS Vaccine Initiative (IAVI) /Batavia

12

Replicating Viral Vector

VSV-S

University of Western Ontario

13

Replicating Viral Vector

VSV vector

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

14

Coroflu (Replicating Viral Vector)

M2-deficient single replication (M2SR) influenza vector; It is designed to build on the backbone of Flugen’s flu vaccine candidate, M2SR, with research inserting gene sequences from SARS-CoV-2, the novel coronavirus that causes COVID-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus

UW–Madison/FluGen/Bharat Biotech

15

Replicating Viral Vector

Newcastle disease virus vector (NDVSARS-CoV-2/Spike)

Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.

16

Replicating Viral Vector

Avian paramyxovirus vector (APMV)

The Lancaster University, UK

1

RNA

LNP-mRNA; mRNA based vaccine for Covid-19; Translate Bio mRNA platform

Translate Bio/Sanofi Pasteur

2

RNA

LNP-mRNA; mRNA based vaccine for Covid-19; Translate Bio mRNA platform

CanSino Biologics/Precision NanoSystems

3

RNA

LNP-encapsulated mRNA cocktail encoding VLP; Developing a COVID-19 mRNA vaccine candidate using mRNA to express the receptor-binding domain of the spike protein of COVID-19 and developing mRNAs that can instruct the host to produce virus-like particles similar to SARS-CoV-2

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

4

RNA

LNP-encapsulated mRNA encoding RBD; Developing a COVID-19 mRNA vaccine candidate using mRNA to express the receptor-binding domain of the spike protein of COVID-19 and developing mRNAs that can instruct the host to produce virus-like particles similar to SARS-CoV-2

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

5

RNA

Replicating Defective SARS-CoV-2 derived RNAs

Centro Nacional Biotecnología (CNB-CSIC), Spain

6

RNA

LNP-encapsulated mRNA

University of Tokyo/ Daiichi-Sankyo

7

RNA

Liposome-encapsulated mRNA

BIOCAD

8

RNA

Several mRNA candidates

RNAimmune, Inc.

9

RNA

mRNA

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

10

mRNA Vaccine (RNA)

mRNA

China CDC/Tongji University/Stermina

11

LUNAR-COV19 (RNA)

mRNA; Developing a COVID-19 mRNA vaccine, LUNAR-COV19, based on the Arcturus' STARR technology and will take advantage of Duke's rapid screening of vaccines

Arcturus/Duke-NUS

12

RNA

saRNA

Imperial College London

13

SARS-CoV-2 mRNA vaccine (RNA)

mRNA; mRNA vaccine for prevention of COVID-19

Curevac

14

RNA

mRNA in an intranasal delivery system; targeting conserved epitopes from the whole CoV-2 genome; integrates 3 different technologies such as eTheRNA's proprietary Trimix technology

eTheRNA

15

mRNA Vaccine (RNA)

mRNA

Greenlight Biosciences

1

VLP

Virus-like particle, based on RBD displayed on virus-like particles

Saiba GmbH

2

Virus-like particle vaccine (VLP)

Plant-derived VLP; Company produced a virus-like particle (VLP) of the coronavirus 20 days after obtaining the SARS-CoV-2 gene

Medicago Inc.

3

VLP

ADDomerTM multiepitope display; Developing preclinically a virus-like particle vaccine using its ADDomer multiepitope display for COVID-19

Imophoron Ltd and Bristol University’s Max Planck Centre

4

VLP

Unknown

Doherty Institute

5

VLP

VLP

OSIVAX

6

VLP

eVLP

ARTES Biotechnology

1

Unknown

Unknown; vaccine for SARS-CoV-2 virus

ImmunoPrecise

2

Unknown

Unknown

Tulane University

3

MAPS vaccine

Multiple Antigen Presenting System (MAPS) vaccine platform is designed to enable the high-affinity binding of protective polysaccharides and proteins in a single vaccine

Affinivax Inc.